5-[6-(4-acetylpiperazin-1-yl)-3-pyridinyl]-2-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]benzonitrile
C24H23N9O2 — CID 126680434
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-[6-(4-acetylpiperazin-1-yl)-3-pyridinyl]-2-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]benzonitrile
5-[6-(4-acetylpiperazin-1-yl)-3-pyridinyl]-2-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]benzonitrile (PubChem CID 126680434) has the molecular formula C24H23N9O2 and a molecular weight of 469.51 g/mol. Its IUPAC name is 5-[6-(4-acetylpiperazin-1-yl)-3-pyridinyl]-2-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]benzonitrile.
Molecular Properties
| Compound Name | 5-[6-(4-acetylpiperazin-1-yl)-3-pyridinyl]-2-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]benzonitrile |
|---|---|
| PubChem CID | 126680434 |
| Molecular Formula | C24H23N9O2 |
| Molecular Weight | 469.51 g/mol |
| Exact Mass | 469.20 |
| IUPAC Name | 5-[6-(4-acetylpiperazin-1-yl)-3-pyridinyl]-2-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]benzonitrile |
| SMILES | CC(=O)N1CCN(c2ccc(-c3ccc(COc4cc(N)nc5n[nH]nc45)c(C#N)c3)cn2)CC1 |
| InChI | InChI=1S/C24H23N9O2/c1-15(34)32-6-8-33(9-7-32)22-5-4-17(13-27-22)16-2-3-18(19(10-16)12-25)14-35-20-11-21(26)28-24-23(20)29-31-30-24/h2-5,10-11,13H,6-9,14H2,1H3,(H3,26,28,29,30,31) |
| InChIKey | AKWGGRKKDRBJQM-UHFFFAOYSA-N |
| XLogP | 2.12 |
| TPSA | 149.94 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 9 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 469.51 |
| LogP ≤ 5 | 2.12 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 9 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 126680434 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.